CRUSH ReportsCRUSH Alerts 2.0CRUSH Industry ReportsCRUSHarmyContact Manager ApplicationMid-Market Manager ApplicationTarget Builder Application
 

Bayer (BAY)

The Bayer CRUSH Report is a Global 500 deep dive sales intelligence company profile and will help increase your sales leads and add more accounts in your sales pipeline while eliminating costly research time.

The Bayer CRUSH Report contains insights to IT architectures, business and technology initiatives, corporate strategies, projects and budgets, org charts and key decision-maker contact info.

The Bayer CRUSH Report allows IT sales and marketing professionals to:
  • Jump-start sales cycles in net new accounts
  • Expand footprints in existing customer accounts
  • Facilitate the strategic account planning process
  • Respond to RFPs & bids more effectively
  • Build better content into executive level presentations
  • Identify the presence of competitors & partners
The Bayer CRUSH Report has the competitive intelligence needed for account planning within the Global 500. Target the right people, with the right message at the right time using our org charts, decision maker contact info, business drivers and IT landscapes.

Click here to download free sample CRUSH Reports

Bayer Corporate News

All internationally relevant press releases from the Bayer Group

Bayer’s Regorafenib Submitted for EU and U.S. Marketing Authorization for the Treatment of Metastatic Colorectal Cancer (for specialized target groups only)
Wednesday May 23rd 2012 12:00:00 PM

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

UK’s NICE recommends Bayer’s Xarelto® (Rivaroxaban) for the Prevention of Stroke in Patients with Non-Valvular Atrial Fibrillation (for specialized target groups only)
Wednesday May 23rd 2012 01:30:00 AM

Positive appraisal based on detailed analysis of the clinical and cost-effectiveness benefits of Xarelto / NICE recommendation gives NHS patients with non-valvular atrial fibrillation (AF) in England and Wales access to the first once-daily, oral stroke prevention tablet since the introduction of warfarin in the 1950s

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Phase III MISSION Trial of Nexavar® in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival (for specialized target groups only)
Tuesday May 22nd 2012 02:30:00 AM

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

"Lebenstagebuch" wins Aspirin Social Award 2012
Thursday May 10th 2012 06:10:00 AM

Berlin institution offers traumatized children of the Second World War unique writing therapy / 2nd place: Ärzte-Netzwerk Berlin (network of physicians in Berlin): Medical care for homeless people / 3rd place: REBOUND: Heidelberg drug prevention program for school students / Bayer Board of Management member Dr. Pott at award ceremony at Humboldt University in Berlin: "Innovative social initiatives with valuable contributions to health care"

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati

Bayer has great potential for the future too
Friday April 27th 2012 03:59:00 AM

Dr. Marijn Dekkers, Chairman of the Board of Management of Bayer AG, and Supervisory Board Chairman Dr. Manfred Schneider (from left) just before the start of the 2012 Annual Stockholders’ Meeting in Cologne.
Fiscal 2011 was strategically and operationally successful / Proposal to raise the dividend for 2011 to EUR 1.65 per share / Encouraging start to 2012 / Good progress with the development of innovative products / Werner Wenning to become Chairman of the Supervisory Board on October 1

(image/jpeg; 0.02 MB)

Blinklist Blogmarks del.icio.us Digg Ma.gnolia My Web 2.0 Newsvine Reddit Segnalo Simpy Spurl Wists Technorati